Allergan (AGN) Tops Q3 EPS by 10c; Issues Strong Q4, FY14 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Deutsche Bank Maintains Buy Rating on Allergen (AGN)
October 27, 2014 1:30 PM EDTDeutsche Bank maintained a Buy rating on Allergen (NYSE: AGN) with a price target of $217. Comments follow Q3 results. Analyst Gregg Gilbert called it a strong quarter, though he noted earnings is not the main story right now.
"AGN reported strong 3Q results, as previously... More
Valeant (VRX) Delivers Letter to Allergan (AGN) Board; Prepared to Boost Offer to $200/Share
October 27, 2014 6:56 AM EDTValeant Pharma (NYSE: VRX) that it has delivered a letter to the Board of Directors of Allergan, Inc. (NYSE: AGN). The text of the letter reads as follows:
October 27, 2014
Board of Directors Allergan, Inc. 2525 Dupont Drive Irvine, California 92612
Dear Board of Directors,
One month ago I extended an olive branch, which was summarily rejected the same day. You have refused all of our offers to meet and answer any questions you may have about Valeant or about our offer. Instead, you have allowed management to... More
